SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Ignyta Appoints Adrian Senderowicz, M.D., as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs

[August 11, 2014]

Ignyta Appoints Adrian Senderowicz, M.D., as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs

SAN DIEGO --(Business Wire)--

Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that Adrian Senderowicz, M.D., has been appointed as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs.

"Adrian's deep experience in clinical, research, development and regulatory affairs in the oncology setting will be extremely valuable to Ignyta," said Jonathan Lim, M.D., Chairman and CEO of Ignyta. "His extensive experience in large pharma and biotech, as well as with the FDA and NCI, will make him instrumental to the company's success as we strive to provide new treatment options for patients with our proprietary oncology drug development programs."

Dr. Senderowicz was most recently Vice President, Global Regulatory Oncology at Sanofi, a position he held from September 2013 to August 2014. At Sanofi, Dr. Senderowicz oversaw the global Sanofi oncology portfolio, including 17 new molecular entities and approximately 250 ongoing oncology and transplant protocols. From July 2012 to March 2013, Dr. Senderowicz was Chief Medical Officer at Tokai Pharmaceuticals, where he wrote the protocol and led the initiation of the ARMOR Phase II clinical trial for the evaluation of galeterone in prostate cancer and played a key role in Tokai's $36 million Series E financing. Dr. Senderowicz held positions of increasing responsibility from July 2008 to March 2012 at Astra Zeneca, including Senior Medical Director, Oncology Clinical Development. At Astra Zeneca, he designed and conducted several global clinical trials in solid tumors, including serving as a Clinical Project Leader of vandetanib, which was approved in the U.S. in April 2011 and the European Union in March 2012, and executing a first-in-human Phase I trial of the Trk inhibitor AZD 6918 as part of the Oncology Phase I Team.

Before his tenure at AstraZeneca, Dr. Senderowicz spent four years in a variety of leadership positions at the U.S. FDA Division of Oncology Drug Products in the Center for Drug Evaluation and Research (CDER), including serving as the Founder and Chairperson of the FDA Clinical Genomics Group at CDER. Prior to his work with the FDA, Dr. enderowicz held a variety of clinical and research positions, including head of the Prostate Cancer Clinic and Chief, Molecular Therapeutics Unit, with the National Cancer Institute/National Institutes of Health. He completed his Internal Medicine Residency training at Mount Sinai School of Medicine, and a Clinical Oncology Fellowship at the National Cancer Institute. Dr. Senderowicz holds both an M.D. and an Instructor of Pharmacology degree from the School of Medicine at the Universidad de Buenos Aires in Argentina.


About Ignyta, Inc.

Ignyta, Inc., located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. Ignyta's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets multiple solid tumor indications, the development of its newly-licensed RXDX-103 and RXDX-104 kinase inhibitors, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. For more information, please visit: www.ignyta.com.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to the expected contributions of Ignyta's new Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs; the company's progress in developing new oncology therapies; and the potential to provide new treatment options for patients. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; regulatory developments in the United States and foreign countries; Ignyta's ability to develop, complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in Ignyta's plans to develop and commercialize its product candidates; the potential for final results of the ongoing Phase I/II clinical trials of RXDX-101, or any future clinical trials, to differ from preliminary results; Ignyta's ability to raise any additional funding it will need to continue to pursue its business and product development plans; Ignyta's ability to obtain and maintain intellectual property protection for its product candidates, including reliance on Nerviano for the prosecution and maintenance of certain key intellectual property for all of Ignyta's in-licensed product candidates; the loss of key scientific or management personnel; competition in the industry in which Ignyta operates; and market conditions. These forward-looking statements are made as of the date of this press release, and Ignyta assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents the company files with the SEC (News - Alert) available at www.sec.gov, including without limitation Ignyta's Annual Report on Form 10-K for the year ended December 31, 2013 and subsequent Quarterly Reports on Form 10-Q.


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy